Genomic landscape and efficacy of HER2-targeted therapy in patients with HER2-mutant non-small cell lung cancer

BACKGROUND: HER2-targeted therapy provides survival benefits to HER2-mutant non-small cell lung cancer (NSCLC). A better understanding of the clinical and genomic characterization of treatment-naïve HER2-positive NSCLC, as well as the efficacy of and resistance to HER2-targeted therapy in HER2-alter...

Descripción completa

Detalles Bibliográficos
Autores principales: Han, Yanjie, Xiong, Yuanyuan, Lu, Tao, Chen, Rongrong, Liu, Yuan, Tang, Hui, Geng, Ruixuan, Wang, Yingyi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2023
Materias:
Oncology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10106648/
https://www.ncbi.nlm.nih.gov/pubmed/37077822
http://dx.doi.org/10.3389/fonc.2023.1121708

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10106648/
https://www.ncbi.nlm.nih.gov/pubmed/37077822
http://dx.doi.org/10.3389/fonc.2023.1121708

Ejemplares similares